1. Supplemental figure 1B
Indicated cell lines were incubated with venetoclax (VEN) in combination with ara-C or idarubicin (IDA), for 48h and viability assessed by flow cytometric exclusion of Sytox Blue and normalised to DMSO. Error bars indicate + SD of a representative experiment run in diuplicate, performed twice. Significant differences (two-tailed t-test p<0.05 and p<0.01) in viability with combination therapy, when present, are indicated as (*) or (**) respectively, calculated by paired t-tests. Combination index values (CI) are shown to indicate the degree of synergy.